Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Avalyn Pharma has drawn in another fundraising round, this time a $100 million oversubscribed series D to continue developing ...

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing ...

Asthma is one of the most common chronic respiratory conditions, with around 300 million people living with the condition ...

Patients with severe asthma who initiate biologics may reduce their risk for oral corticosteroids (OCS)-related new-onset adverse outcomes.

Whilebiological drugs or biologics have improved the lives of many people with severe asthma, a new study shows that some ...

Considering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.

There is no clear FDA framework for inhalable biologics. Each product is evaluated case-by-case. That’s bureaucratic speak ...

Risk aversion to steroid side effects shaped treatment choices, underscoring support for tailored approaches in managing ...

New research suggests that expectations are associated with asthma outcomes. People who thought more negatively about their ...

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...